Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Exploring “ADC + Antibody” as an Emerging Combination Strategy for Solid Tumor Therapies

Exploring “ADC + Antibody” as an Emerging Combination Strategy for Solid Tumor Therapies

10:30 am - Monday 12th October 2026

Explaining rationale for combining a HER2 ADC with trastuzumab
Describing preclinical and clinical results of combination trials, highlighting clinical benefit of ADC antibody combinations
Investigating mechanism to understand how antibody combination helps ADC overcome binding site barrier to improve tumor penetration and improve efficacy

Speakers:

Peng Guo

Peng Guo

Professor

Hangzhou Institute of Medicine, Chinese Academy of Sciences